Volume 3 Number 6
 June 2015

Home > Publications > Recurrent Prostate Cancer > Volume 3 - Year 2015 > Number 6, June 2015

Contents


Case reports

Hutton R, Maguire J, Amer T, Fitzpatrick J, Hasan R, Ablett M, Meddings R.
Intracranial metastasis of adenocarcinoma of the prostate presenting with symptoms of spinal cord compression.
Indian J Surg. 2015 Apr;77(Suppl 1):75-6. doi: 10.1007/s12262-014-1143-1. Epub 2014 Jul 23.
Abstract | Similar articles

Madan R, Singh L, Haresh KP, Rath GK.
Metastatic Adenocarcinoma of Prostate in a 28-Year-Old Male: The outcome is poor in young patients?
Indian J Palliat Care. 2015 May-Aug;21(2):242-4. doi: 10.4103/0973-1075.156510.
Abstract | Full text | Similar articles

McNamara MA, George DJ.
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
BMC Cancer. 2015 May 7;15:371. doi: 10.1186/s12885-015-1390-y.
Abstract | Full text | Similar articles

Detection, diagnosis and evaluation

Bourdoumis A, Chrisofos M, Stasinou T, Christopoulos P, Mourmouris P, Kostakopoulos A, Deliveliotis C.
The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Anticancer Res. 2015 May;35(5):3075-9.
Abstract | Similar articles

Aragon-Ching JB, Siegel RS, Frazier H 2nd, Andrawis R, Hendricks F, Phillips M, Jarrett T, Guebre-Xabiher H, Patierno S, Simmens SJ.
Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
Clin Genitourin Cancer. 2015 Apr 18. pii: S1558-7673(15)00075-0. doi: 10.1016/j.clgc.2015.04.003. [Epub ahead of print]
Abstract | Similar articles

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ.
68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
Eur J Nucl Med Mol Imaging. 2015 May 15. [Epub ahead of print]
Abstract | Similar articles

Heidenreich A.
Choline-positron emission tomography/CT in patients with relapsing prostate cancer: to be performed with therapeutic consequences only.
BJU Int. 2015 Jun;115(6):849-50. doi: 10.1111/bju.12995.
Abstract | Full text | Similar articles

Luna A, Vilanova JC, Alcalá Mata L.
[Total body MRI in early detection of bone metastasis and its indication in comparison to bone scan and other imaging techniques].
Arch Esp Urol. 2015 Apr;68(3):371-90.
Abstract | Similar articles

Mocarska A, Czarnocki K, Starosławska E, Janczarek M, Zelazowska-Cieslińska I, Losicki M, Burdan F.
[Evaluation of prostate cancer progression].
Pol Merkur Lekarski. 2014 Dec;37(222):356-64. Polish.
Abstract | Related citations

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
Clinical utility of (18) F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.
Abstract | Full text | Similar articles

Sridharan S, Macias V, Tangella K, Kajdacsy-Balla A, Popescu G.
Prediction of prostate cancer recurrence using quantitative phase imaging.
Sci Rep. 2015 May 15;5:9976. doi: 10.1038/srep09976.
Abstract | Full text | Similar articles

Vagnoni V, Brunocilla E, Bianchi L, Porreca A, Borghesi M, Pultrone CV, Angelo P, Chessa F, Ceci F, Mengoni F, Dababneh H, Castellucci P, Fanti S, Martorana G, Schiavina R.
State of the PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer.
Arch Esp Urol. 2015 Apr;68(3):354-370.
Abstract | Similar articles

Prostate-specific antigen
Garzotto M.
Prostate-specific Antigen Kinetics in the Management of Prostate Cancer.
ASCO 2011 Educational Book
Abstract | Full text

Etiology and pathogenesis

Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P.
The hallmarks of castration-resistant prostate cancers.
Cancer Treat Rev. 2015 May 9. pii: S0305-7372(15)00098-5. doi: 10.1016/j.ctrv.2015.05.003. [Epub ahead of print]
Abstract | Similar articles

Quayle L, Ottewell PD, Holen I.
Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer.
Curr Cancer Drug Targets. 2015 May 5. [Epub ahead of print]
Abstract | Similar articles

Integrative medicine

Bernichtein S, Pigat N, Capiod T, Boutillon F, Verkarre V, Camparo P, Viltard M, Méjean A, Oudard S, Souberbielle JC, Friedlander G, Goffin V.
High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions.
PLoS One. 2015 May 4;10(5):e0125423. doi: 10.1371/journal.pone.0125423. eCollection 2015.
Abstract | Full text | Similar articles

Orellana-Serradell O, Poblete CE, Sanchez C, Castellón EA, Gallegos I, Huidobro C, Llanos MN, Contreras HR.
Proapoptotic effect of endocannabinoids in prostate cancer cells.
Oncol Rep. 2015 Apr;33(4):1599-608. doi: 10.3892/or.2015.3746. Epub 2015 Jan 21.
Abstract | Full text | Similar articles

Twardowski P, Kanaya N, Frankel P, Synold T, Ruel C, Pal SK, Junqueira M, Prajapati M, Moore T, Tryon P, Chen S.
A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.
Cancer. 2015 May 18. doi: 10.1002/cncr.29421. [Epub ahead of print]
Abstract | Similar articles

Yang M, Kenfield SA, Van Blarigan EL, Wilson KM, Batista JL, Sesso HD, Ma J, Stampfer MJ, Chavarro JE.
Dairy intake after prostate cancer diagnosis in relation to disease-specific and total mortality.
Int J Cancer. 2015 May 20. doi: 10.1002/ijc.29608. [Epub ahead of print]
Abstract | Similar articles

Overall management

Armstrong AJ.
New treatment options in castration-resistant prostate cancer.
J Natl Compr Canc Netw. 2015 May;13(5 Suppl):690-3.
Abstract | Similar articles

Beck AC, Mooney K.
Caring for the life you saved.
Oncology (Williston Park). 2015 Apr;29(4):240-8.
Abstract | Full text | Similar articles

Chopra S, Rashid P.
Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Aust Fam Physician. 2015;44(5):302-5.
Abstract | Full text | Similar articles

Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.
Castration-resistant prostate cancer: AUA Guideline. Update April 2015.
American Urological Association official website, accessed 2015 Jun 15.
Abstract | Full text | Flowchart | ECOG |
Similar articles

Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.
Castration-resistant prostate cancer: AUA Guideline.
J Urol. 2013 Aug;190(2):429-38. doi: 10.1016/j.juro.2013.05.005. Epub 2013 May 9.
Abstract | Full text | Similar articles

Gomella LG, Petrylak DP, Shayegan B.
Current management of advanced and castration resistant prostate cancer.
Can J Urol. 2014 Apr;21(2 Supp 1):1-6.
Abstract | Full text | Similar articles

MacVicar GR.
Metastatic Castration-resistant Prostate Cancer 2011: Exciting Advances, New Challenges.
ASCO 2011 Educational Book
Abstract | Full text

Sartor O.
State-of-the-Art Management for the Patient with Castration-Resistant Prostate Cancer in 2012.
Am Soc Clin Oncol Educ Book. 2012:289-91. doi: 10.14694/EdBook_AM.2012.32.289.
Abstract | Full text | Similar articles

Shah M, Denlinger CS.
Optimal post-treatment surveillance in cancer survivors: is more really better?
Oncology (Williston Park). 2015 Apr 15;29(4):230-40.
Abstract | Full text | Similar articles

Sternberg CN, Petrylak DP, Madan RA, Parker C.
Progress in the treatment of advanced prostate cancer.
Am Soc Clin Oncol Educ Book. 2014:117-31. doi: 10.14694/EdBook_AM.2014.34.117.
Abstract | Full text | Similar articles

Prognosis and outcome

Chen Z, Chen N, Shen P, Gong J, Li X, Zhao T, Liao B, Liu L, Liu Z, Zhang X, Liu J, Peng Z, Chen X, Xu M, Gui H, Zhang P, Wei Q, Zhou Q, Zeng H.
The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer.
Prostate. 2015 Apr 27. doi: 10.1002/pros.23005. [Epub ahead of print]
Abstract | Similar articles

Choo MS, Cho SY, Jeong CW, Lee SB, Ku JH, Hong SK, Byun SS, Kwak C, Kim HH, Lee SE, Jeong H.
Predictors of positive surgical margins and their location in Korean men undergoing radical prostatectomy.
Int J Urol. 2014 Sep;21(9):894-8. doi: 10.1111/iju.12465. Epub 2014 May 8.
Abstract | Full text | Similar articles

Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M 3rd, Lawton CA, Sandler HM.
Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413.
Cancer. 2015 Mar 15;121(6):844-52. doi: 10.1002/cncr.29146. Epub 2014 Nov 19.
Abstract | Similar articles

Kozal S, Peyronnet B, Cattarino S, Seisen T, Comperat E, Vaessen C, Mozer P, Renard-Penna R, Cussenot O, Rouprêt M, Drouin SJ.
Influence of pathological factors on oncological outcomes after robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective study.
Urol Oncol. 2015 Jul;33(7):330.e1-7. doi: 10.1016/j.urolonc.2015.03.020. Epub 2015 May 18.
Abstract | Similar articles

Kryvenko ON, Epstein JI.
Re: Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer.
Pathology. 2015 Jun;47(4):394. doi: 10.1097/PAT.0000000000000263.
Abstract | Similar articles

Kumar A, Samavedi S, Bates AS, Cuevas CA, Coelho RF, Rocco B, Palmer K, Patel VR.
Age stratified comparative analysis of perioperative, functional and oncologic outcomes in patients after robot assisted radical prostatectomy - A propensity score matched study.
Eur J Surg Oncol. 2015 Jul;41(7):837-43. doi: 10.1016/j.ejso.2015.04.006. Epub 2015 Apr 25.
Abstract | Similar articles

Lepor H, Llukani E, Sperling D, Fütterer JJ.
Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer.
Eur Urol. 2015 May 12. pii: S0302-2838(15)00331-0. doi: 10.1016/j.eururo.2015.04.029. [Epub ahead of print]
Abstract | Similar articles

Lo AC, Morris WJ, Pickles T, Keyes M, McKenzie M, Tyldesley S.
Patterns of recurrence after low-dose-rate prostate brachytherapy: a population-based study of 2223 consecutive low- and intermediate-risk patients.
Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):745-51. doi: 10.1016/j.ijrobp.2014.12.014.
Abstract | Similar articles

Liu JJ, Lichtensztajn DY, Gomez SL, Sieh W, Chung BI, Cheng I, Brooks JD.
Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer.
Pathology. 2014 Jun;46(4):306-10. doi: 10.1097/PAT.0000000000000097.
Abstract | Full text | Similar articles

Luo Q, Yu XQ, Smith DP, O'Connell DL.
A population-based study of progression to metastatic prostate cancer in Australia.
Cancer Epidemiol. 2015 May 13. pii: S1877-7821(15)00095-8. doi: 10.1016/j.canep.2015.04.013. [Epub ahead of print]
Abstract | Similar articles

Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ.
Positive Surgical Margins in Radical Prostatectomy Patients Do Not Predict Long-term Oncological Outcomes: Results from SEARCH.
BJU Int. 2015 May 24. doi: 10.1111/bju.13181. [Epub ahead of print]
Abstract | Similar articles

Miyoshi Y, Noguchi K, Yanagisawa M, Taguri M, Morita S, Ikeda I, Fujinami K, Miura T, Kobayashi K, Uemura H.
Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer.
BMC Cancer. 2015 May 1;15:338. doi: 10.1186/s12885-015-1330-x.
Abstract | Full text | Similar articles

Nini A, Gandaglia G, Fossati N, Suardi N, Cucchiara V, Dell'Oglio P, Cazzaniga W, Luzzago S, Montorsi F, Briganti A.
Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.
Eur Urol. 2015 May 8. pii: S0302-2838(15)00377-2. doi: 10.1016/j.eururo.2015.04.035. [Epub ahead of print]
Abstract | Similar articles

Pettenati C, Neuzillet Y, Radulescu C, Hervé JM, Molinié V, Lebret T.
Positive surgical margins after radical prostatectomy: What should we care about?
World J Urol. 2015 May 5. [Epub ahead of print]
Abstract | Similar articles

Poulsen MH, Rasmussen J, Edenbrandt L, Høilund-Carlsen PF, Gerke O, Johansen A, Lund L.
Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
BJU Int. 2015 Apr 24. doi: 10.1111/bju.13160. [Epub ahead of print]
Abstract | Similar articles

Siadat F, Sykes J, Zlotta AR, Aldaoud N, Egawa S, Pushkar D, Kuk C, Bristow RG, Montironi R, van der Kwast T.
Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series.
Prostate. 2015 May 11. doi: 10.1002/pros.23009. [Epub ahead of print]
Abstract | Similar articles

Sieh W, Lichtensztajn DY, Gomez SL, Liu JJ, Chung BI, Cheng I, Brooks JD.
Re: Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer: authors' reply.
Pathology. 2015 Jun;47(4):394-5. doi: 10.1097/PAT.0000000000000264.
Abstract | Similar articles

Takada S, Tamaki S, Nagamori S, Endou M.
[Risk factors for predicting severe leukopenia induced by docetaxel plus prednisolone in patients with Castration-Resistant Prostate cancer].
Gan To Kagaku Ryoho. 2015 May;42(5):591-4. Japanese.
Abstract | Similar articles

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, Okajima E, Hirayama A, Hirao Y, Fujimoto K.
Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
BMC Cancer. 2015 May 20;15(1):420. doi: 10.1186/s12885-015-1429-0.
Abstract | Full text | Similar articles

Quality of life

Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, Johansson E, Stattin P, Fransson P.
Population-based study of long-term functional outcomes after prostate cancer treatment.
BJU Int. 2015 May 8. doi: 10.1111/bju.13179. [Epub ahead of print]
Abstract | Similar articles

Treatment

Armstrong AJ.
New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?
Eur Urol. 2014 Feb;65(2):300-2. doi: 10.1016/j.eururo.2013.08.059. Epub 2013 Sep 10.
Abstract | Full text | Similar articles

Ali Shah SI.
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer.
South Asian J Cancer. 2015 Apr-Jun;4(2):95-7. doi: 10.4103/2278-330X.155699.
Abstract | Full text | Similar articles

Bahl A, Persad R.
Metastatic castrate-resistant prostate cancer: New landscape, new challenges
British Journal of Medical and Surgical Urology 2011 4: S9. DOI: 10.1016/j.bjmsu.2011.05.003. Sep 1, 2011
Abstract | Full text

Bajaj M, Heath EI.
New developments in prostate cancer therapy.
Am Soc Clin Oncol Educ Book. 2012:309-13. doi: 10.14694/EdBook_AM.2012.32.309.
Abstract | Full text | Similar articles

Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BF.
Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.
Eur Urol. 2015 May 20. pii: S0302-2838(15)00378-4. doi: 10.1016/j.eururo.2015.04.036. [Epub ahead of print]
Abstract | Similar articles

Bitting RL, Armstrong AJ.
Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.
Am Soc Clin Oncol Educ Book. 2012:292-7. doi: 10.14694/EdBook_AM.2012.32.292.
Abstract | Full text | Similar articles

Chi KN, Nguyen PL, Higano CS.
Androgen deprivation for prostate cancer: when and how, the good and the bad.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e176.
Abstract | Full text | Similar articles

Chi KN, Drake CG, Flaig TW.
Systemic Therapy for Castration-resistant Prostate Cancer: Novel Agents and New Standards.
ASCO 2011 Educational Book
Abstract | Full text

Conteduca V, Caffo O, Derosa L, Veccia A, Petracci E, Chiuri VE, Santoni M, Santini D, Fratino L, Maines F, Testoni S, De Giorgi U.
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
Prostate. 2015 May 15. doi: 10.1002/pros.23014. [Epub ahead of print]
Abstract | Similar articles

Dorff TB, Gross ME.
Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
Am Soc Clin Oncol Educ Book. 2015;35:e270-3. doi: 10.14694/EdBook_AM.2015.35.e270.
Abstract | Full text | Similar articles

Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J, Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN.
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.
Invest New Drugs. 2015 May 19. [Epub ahead of print]
Abstract | Similar articles

Fizazi K, Jenkins C, Tannock IF.
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
Ann Oncol. 2015 May 22. pii: mdv245. [Epub ahead of print]
Abstract | Full text | Similar articles

Fizazi K.
Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and others.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e161.
Abstract | Full text | Similar articles

Gulley JL, Madan RA, Heery CR.
Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e166.
Abstract | Full text | Similar articles

Hernandez-Aya LF, Hussain M.
Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer.
Am Soc Clin Oncol Educ Book. 2015;35:e263-9. doi: 10.14694/EdBook_AM.2015.35.e263.
Abstract | Full text | Similar articles

Hernandez-Aya LF, Hussain M.
Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress, Ongoing Discoveries.
ASCO 2015 Genitourinary Cancers Symposium, Jan 30, 2014.
Abstract | Full text

Hussain M, DiPaola RS.
Clinical research in metastatic prostate cancer: a focus on impact and value.
Am Soc Clin Oncol Educ Book. 2015;35:17-21. doi: 10.14694/EdBook_AM.2015.35.17.
Abstract | Full text | Similar articles

Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY.
Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Eur Urol. 2015 May 21. pii: S0302-2838(15)00410-8. doi: 10.1016/j.eururo.2015.05.009. [Epub ahead of print]
Abstract | Similar articles

Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M 3rd, Chang AJ, Chan JM, Simko JP, Carroll PR.
Patterns of Local Failure Following Radiation Therapy for Prostate Cancer.
J Urol. 2015 May 14. pii: S0022-5347(15)03944-0. doi: 10.1016/j.juro.2015.04.111. [Epub ahead of print]
Abstract | Similar articles

El-Amm J, Aragon-Ching JB.
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
Ther Adv Med Oncol. 2013 Jan;5(1):25-40. doi: 10.1177/1758834012458137.
Abstract | Full text | Similar articles

Logothetis CJ, Beer TM, de Bono JS, Saad F.
Metastatic Castration-Resistant Prostate Cancer: New Targets, New Therapeutic Approaches

Medscape Education Oncology, 2012 Mar 28.
Abstract | Full text

Mofid B, Azghandi S, Rezazadeh Mafi A.
Complete radiologic response in metastatic castration-resistant prostate cancer treated with cabazitaxel.
Iran J Med Sci. 2015 May;40(3):294-6.
Abstract | Full text | Similar articles

Nilsson S.
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Expert Opin Drug Saf. 2015 May 28:1-10. [Epub ahead of print]
Abstract | Similar articles

Payne HA, Farnham C, Kirby M, Troup J.
Advanced prostate cancer – optimising and integrating care. Meeting report.
Trends in Urology & Men's Health, Article first published online: 28 Jan 2013. DOI: 10.1002/tre.314.
Abstract | Full text

Petrioli R, Francini E, Fiaschi AI, Laera L, Miano ST, DE Rubertis G, Roviello G.
Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.
Anticancer Res. 2015 May;35(5):3097-102.
Abstract | Similar articles

Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P, Renard-Penna R, Salin A, Lebret T, Villers A, Soulié M, Taille A, Flamand V.
Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature.
J Urol. 2015 May 8. pii: S0022-5347(15)03911-7. doi: 10.1016/j.juro.2015.04.103. [Epub ahead of print]
Abstract | Similar articles

Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ.
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
Anticancer Drugs. 2015 May 20. [Epub ahead of print]
Abstract | Full text | Similar articles

Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ.
Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302.
Eur Urol. 2015 May 15. pii: S0302-2838(15)00374-7. doi: 10.1016/j.eururo.2015.04.032. [Epub ahead of print]
Abstract | Similar articles

Slovin SF.
Immunotherapeutic approaches in prostate cancer: combinations and clinical integration.
Am Soc Clin Oncol Educ Book. 2015;35:e275-83. doi: 10.14694/EdBook_AM.2015.35.e275.
Abstract | Full text | Similar articles

Small EJ, Raymond L, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND.
A randomized phase II trial of sipuleucel-T with concurrent vs sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer.
Clin Cancer Res. 2015 Apr 29. pii: clincanres.0079.2015. [Epub ahead of print]
Abstract | Full text | Similar articles

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11.
Abstract | Full text | Similar articles

Thibault C, Massard C.
[New therapies in metastatic castration resistant prostate cancer].
Bull Cancer. 2015 May 25. pii: S0007-4551(15)00156-3. doi: 10.1016/j.bulcan.2015.04.016. [Epub ahead of print]
Abstract | Similar articles

Enzalutamide
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.
Enzalutamide in metastatic prostate cancer before chemotherapy.
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.
Abstract | Full text | PubMed citation | Similar articles

Merseburger AS, Haas GP, von Klot CA.
An update on enzalutamide in the treatment of prostate cancer.
Ther Adv Urol. 2015 Feb;7(1):9-21. doi: 10.1177/1756287214555336
Abstract | Full text | Similar articles

Ramadan WH, Kabbara WK, Al Basiouni Al Masri HS.
Enzalutamide for patients with metastatic castration-resistant prostate cancer.
Onco Targets Ther. 2015 Apr 17;8:871-6. doi: 10.2147/OTT.S80488. eCollection 2015.
Abstract | Full text | Similar articles

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.
Increased survival with enzalutamide in prostate cancer after chemotherapy.
N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.
Abstract | Full text | PubMed citation | Similar articles

Neoadjuvant androgen ablation before radical prostatectomy
Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group.
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
J Urol. 2001 Aug;166(2):500-6; discussion 506-7.
Abstract | Similar articles

Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S; Canadian Uro-Oncology Group.
Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy.
J Urol. 2003 Sep;170(3):791-4.
Abstract | Similar articles

Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A; Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
J Urol. 2002 Jan;167(1):112-6.
Abstract | Similar articles

Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A.
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
J Urol. 1995 Aug;154(2 Pt 1):424-8.
Abstract | Similar articles

Taneja SS.
Re: Intense Androgen-Deprivation Therapy with Abiraterone Acetate plus Leuprolide Acetate in Patients with Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study.
J Urol. 2015 Jun;193(6):1983. doi: 10.1016/j.juro.2015.03.046. Epub 2015 Mar 14.
Abstract | Full text | Similar articles

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.
Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study.
J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.
Abstract | Related citations

Primary androgen deprivation therapy
Sammon JD, Abdollah F, Reznor G, Pucheril D, Choueiri TK, Hu JC, Kim SP, Schmid M, Sood A, Sun M, Kibel AS, Nguyen PL, Menon M, Trinh QD.
Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Eur Urol. 2015 Jul;68(1):32-9. doi: 10.1016/j.eururo.2014.10.018. Epub 2014 Oct 29.
Abstract | Full text | Similar articles

Taneja SS.
Re: patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer.
J Urol. 2015 Jun;193(6):1982-3. doi: 10.1016/j.juro.2015.03.045. Epub 2015 Mar 14.
Abstract | Full text | Similar articles

 

This website is certified by Health On the Net Foundation. Click to verify. www.prostate-cancer-today.org
Home Prostate OncologyRecurrent Prostate Cancer
LibraryPublications
About UsE-mail Alert ServiceJournals Privacy Policy